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The determinants of adherence and nonadherence span a broad ecologic spectrum. Medication adherence has 
different domains of influence at the individual (biologics and efficacy of drugs, psychosocial factors such as 
health literacy, self-efficacy), and societal levels (health care insurance coverage and out of pocket costs, access 
to transportation etc.). The presentations during this session centered on the stated domains of influence 
above. 
 
Question posed for discussion: Given this varying range of adherence determinants, as researchers, do we focus 
on a range of interventions to address these influencing factors, or rather, have multifaceted interventions that 
addresses all the levels of influence on adherence?  
 
Audience remarks: Members of the audience stated the need for more tailored interventions for patients. All 
patients do not need to receive the same type of intervention. There is however difficulty with developing 
interventions when every patients’ reason for adherence is different. Other comments discussed the need to 
use the explanatory model to understand patients’ perception of their illness and why they may not take their 
medicines. Also, understanding the medication use experience of patients is critical and pharmacists need to 
pay attention to each individuals’ experience. There was discussion on the need to incentivize patients to 
adhere and if this was common or another way to deal with adherence. Overall, as researchers, scientists, and 
pharmacists, we should understand that medication adherence is a complex problem we have studied for 
decades with no final solution. However, we have made lots of progress in understanding the problem and 
developing interventions, but now, our future work demands a focus on tailored interventions that specifically 
meet patients’ needs.  
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ABSTRACT 
Introduction: Medicaid patients are in poorer health, suffer a higher incidence of comorbidities and polypharmacy compared 
to the general population and may be at increased risk of Adverse Drug Reactions (ADRs). Using a previously collected 
database of Medicaid patients, this study will examine the association between estimated ADR incidence and drug adherence. 
The ADverse Drug Reaction/Event Screening System (ADDRESS) dataset provides incidence estimates top ADRs for each drug, 
which when combined provide a probabilistic incidence of ADRs (the drug’s ADR “misery index”).  Combining the ADR misery 
indexes for each drug on the patient’s regimen provides the patient’s overall ADR misery index. It will then be possible to 
explore associations between adherence and individual ADR incidence, total drug ADR incidence, and drug regimen ADR 
incidence.   
 
Proposed Method: The ADDRESS database lists the incidence rates of all observed ADR symptom clusters for each drug, by 
synthesizing data on ADR incidence from the literature. For each patient, a list of all drugs taken will be extracted from the 
Medicaid dataset, and the Drug ADR misery for all of the patients’ medications combined to derive total ADR misery, the 
probable ADR incidence for the patient’ entire drug regimen. 
 
The study will test if an association exists between individual drug adherence and drug ADR misery index, between total drug 
regimen ADR misery index and regimen adherence, if the strength of association between adherence and ADR misery will 
differ across drug indications, and if the association between adherence and ADR misery differs across different disease 
states. 
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ABSTRACT 
Objectives: Though biologic disease modifying anti-rheumatic drugs (bDMARDs) have shown higher efficacy and better 
tolerance in clinical trials than conventional disease modifying anti-rheumatic drugs (cDMARDs), their cost could potentially 
affect patient adherence. The objective of this study was to estimate adherence to bDMARDs and cDMARDs in patients with 
Rheumatoid Arthritis (RA), and to assess if adherence is associated with drug class (bDMARDs vs cDMARDs) or patient out-
of-pocket (OOP) costs. 
Methods: Patients with RA from the 2008-2012 Medicare Current Beneficiary Survey (MCBS) data with at least 2 Medicare 
Part D claims were included. Medication adherence was calculated as proportion of days covered (PDC) in a six-month period 
following date of first medication fill. Individuals with PDCs>=0.80 were considered adherent. Total OOP medication costs per 
patient were generated as a sum of imputed OOP costs per claim. Logistic regression was used to assess associations between 
adherence and class of drug and OOP costs. 
Results: 542 patients met inclusion criteria. 85% were on cDMARDs. The proportion (95% confidence interval) of patients 
adherent to bDMARDs, 0.48, (0.40, 0.56), did not differ significantly from that for cDMARDs, 0.52, (0.47. 0.56) (p=0.1293). 
Patients on bDMARDs had significantly higher mean OOP costs ($922.86±1720) than patients on cDMARDs ($40.26±51.93).  
In univariate logistic regressions, there was no significant association between DMARD type (p=0.13) and adherence, or OOP 
costs (p=0.72) and adherence. In a multivariate logistic model, there was a trend towards bDMARDs having lower adherence 
(O.R.=0.6, 95% C.I. (0.351, 1.032)) than cDMARDs, but the difference was not significant (p=0.06).  
Conclusion: Adherence to DMARD therapy in patients with RA was relatively low at approximately one-half, and did not differ 
significantly between patients on biologic DMARDs (0.48±0.08) and those on conventional DMARDs (0.52±0.04), although 
patients on bDMARDs paid more out-of-pocket on an average as compared to patients on cDMARDs.  
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ABSTRACT 
Introduction: Among women with estrogen receptor positive (ER+) breast cancer, adjuvant treatment with tamoxifen 
significantly reduces the risk of recurrence and breast cancer mortality during and after treatment. However, poor adherence 
and persistence to therapy adversely impact patient outcomes. An understanding of how costs and effect size affect the cost-
effectiveness of adherence interventions is needed for improved development of such interventions. 
Objective: To evaluate benefits needed for a hypothetical pharmacist-led adherence intervention to be considered cost-
effective at a threshold of $100,000 per quality-adjusted life years (QALY) gained for patients with prior breast cancer on 
tamoxifen adjuvant therapy as compared to usual care from an insurer’s perspective. 
Methods: A five-state Markov model was developed to evaluate the adherence intervention compared to no intervention. 
Annual cycles and a five-year time horizon were used. A systematic review of the literature was conducted to identify the risk 
of breast cancer recurrence at varying levels of adherence and persistence. Clinical model inputs, costs, and utilities were 
similarly identified. Tamoxifen cost was based on wholesale acquisition cost; effectiveness was measured in terms of QALY 
gained. Relative improvement in adherence or persistence was varied and the associated program cost was estimated for 
assessing incremental cost-effectiveness at a willingness-to-pay (WTP) threshold of $100,000/QALY. 
Results: In the first year, 75% of patients remained persistent, 93% of which were adherent. An annual program cost of $198 
would need to result in a 7% relative (6.5% absolute) improvement in adherence to be cost-effective. An annual program cost 
of $155 would need to result in a 10% relative (7.5% absolute) improvement in persistence to be cost-effective.  
Conclusion: Programs need to cost <$200 per year to be considered cost-effective if producing small gains in adherence, if 
impacting adherence or persistence separately. Programs with higher cost must demonstrate significant gains in either 
adherence or persistence, or impact both measures.  
 
Key Words: Breast Cancer, Cancer, Medication Adherence, Recurrence, Tamoxifen, Adjuvant 
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ABSTRACT 
Introduction: On April 1st, 2014, Medicaid coverage for childless adults in Wisconsin was expanded through an amended 
section 1115 demonstration waiver. In the new waiver, prescription drug benefit was expanded via copayment reductions 
and a drug formulary expansion.  
 
Objective: To identify the effects of expanded drug coverage on medication adherence for oral antidiabetic drugs in childless 
adults having type II diabetes. 
 
Methods: A pre-test, post-test study with a non-equivalent control group was conducted using Wisconsin Medicaid 
administrative enrollment records, medical and drug claims data. The study period was from April 2013 to March 2015 to 
include one full year before and after the effective date of the coverage expansion. Medication adherence was measured 
using proportion of days covered (PDC). PDC for at least one drug from the four most commonly used oral antidiabetic drug 
classes was calculated, and then the percentage of patients who met the threshold of PDC ≥ 0.8 was identified. Difference-
in-difference analysis was performed to compare changes in the adherent percentage among the childless adults with 
parents/caretakers. 
 
Results: The study population included 1,158 childless adults and 4,128 parents/caretakers. In the pre-period, the percentage 
of adherent patients (PDC ≥ 0.8) for at least one drug from the four classes was 74% in the childless adults and 60% in the 
parents/caretakers. A fully adjusted difference-in-difference OLS regression showed it significantly increased by 6% points (p 
= 0.01) in the childless adults compared to the parents/caretakers.  
 
Conclusion: Medication adherence for oral antidiabetic drugs was slightly but significantly improved in the low-income 
childless adults after the drug coverage expansion.  
 
Implications: Drug insurance affects medication adherence as it can directly determine the accessibility and affordability of 
the drugs. Policymakers need to design drug insurance coverage to ensure appropriate treatment of chronic conditions for 
low-income childless adults. 
 
 
Key Words: Medicaid, Drug insurance coverage, Medication adherence, Diabetes, Childless adults 
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ABSTRACT 
Introduction: Non-adherence continues to be a barrier to achieving optimum health outcomes in patients with type 2 
diabetes. Prior research shows that health literacy has an indirect impact on diabetes medication adherence via several 
contributing factors. Though these existing studies identified several barriers and facilitators to medication adherence, 
limited research empirically investigates these barriers and facilitators across different levels of patients’ health literacy. 
Understanding the factors that facilitate or hinder patients’ diabetes medication adherence across different health literacy 
levels may lead to the development of health literacy tailored adherence interventions to improve diabetes care. 
 
Objective: This study aims to examine whether the contributing factors to medication nonadherence among patients with 
type 2 diabetes differ across health literacy levels. Also, we will compare the similarities and differences in contributing factors 
to medication nonadherence across participants from different health literacy levels.  
 
Theoretical framework: The Health Literacy Pathway Model will identify the interpersonal and intrapersonal factors that 
could contribute to medication adherence. These include interpersonal factors such as self-efficacy for medication use, 
perceived barriers related to medication nonadherence, belief about medicines, and intrapersonal factors such as provider-
patient communication.  
 
Proposed methods: This cross-sectional study will be conducted using a convergent mixed methods design. Participants with 
a diagnosis of type 2 diabetes, who are at least 20 years, understand English, and have been prescribed at least one diabetes 
medicine will be included. A face-to-face survey will be administered to 300 participants to investigate differences in factors 
contributing to medication adherence across health literacy levels. Subsamples of 6 participants will be purposively selected 
from each health literacy level (i.e. adequate and inadequate) and two medication adherence levels (i.e. low and high), 
assessed by the Newest Vital Sign and the Adherence to Refills and Medications Scale, respectively. A 60-minute face-to-face 
semi-structured interview will further explore factors contributing to medication adherence across health literacy levels. By 
merging the results from the survey and interview, we will understand the barriers and facilitators of medication adherence 
in patients with different levels of health literacy and medication adherence. 
 
 
Key Words: barriers, diabetes, facilitators, health literacy, medication adherence 
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ABSTRACT 
Introduction: The standard Medicare Part D benefit contains a gap in coverage (or so-called “doughnut hole”) which requires 
beneficiaries to pay 100% of the cost for prescription drugs until they reach the catastrophic coverage phase. This coverage 
gap has been linked to financial burden for beneficiaries resulting in poor medication adherence. Under the Affordable Care 
of Act (ACA), the coverage gap has been phasing out gradually since 2011, which will be completed filled by 2020 such that 
beneficiaries will only pay 25% of drug costs.   
Objective: This study aims to estimate the impact of closing the coverage gap under the ACA on out-of-pocket (OOP) burden 
and access to prescription drugs for Part D beneficiaries, particularly in those with cancer. In order to achieve these goals, 
this study have three objectives: (1) to examine the changes in drug utilization and OOP costs for all Part D beneficiaries, (2) 
to examine the changes in drug utilization and OOP costs for Part D beneficiaries with cancer, and (3) to estimate the impact 
of the closing the gap on access to drugs.  
Theoretical Framework: Based on the Andersen’s Behavioral Model of Health Services Use, a conceptual model is developed 
and the detailed variables will be identified. This model proposes the individual characteristics influencing health behaviors 
such as drug use and expenditures, which, in turn, affect associated outcomes such as out-of-pocket burden or access to 
drugs. 
Proposed Methods: Data will be obtained from 2008 through 2015 Medicare Current Beneficiary Survey data. The sample 
will include non-disabled Part D beneficiaries with and without low-income subsidies, which will be a comparison and 
treatment group, respectively. A difference-in-differences approach will be employed to measure the changes in outcome of 
interests among both the treatment and the comparison group for all beneficiaries and those with cancer after the ACA.  
 
 
Key Words: Medicare Part D, Coverage Gap, Drug utilization, Out-of-pocket Burden, Access to Care 
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ABSTRACT 
Introduction: Oral anticoagulation therapies, such as warfarin, require frequent clinic visits for close monitoring and dose 
adjustments to ensure optimal control within a narrow therapeutic range. Poor health outcomes have been identified in 
individuals with longer travel time and distance to clinics.1 Individuals with transportation barriers have also been reported 
to have reduced access to medications and pharmacies. Transportation is one of several socio-environmental factors 
identified to indirectly impact adherence to chronic therapies.2 While transportation barriers, such as travel distance and 
time, have been shown to negatively impact health outcomes, such data are lacking in patients on chronic anticoagulation 
who necessitate frequent access to care. Objective: To explore whether a relationship exists between patient’s travel distance 
and time to dispensing pharmacies and the quality of anticoagulation control in an urban population of patients on warfarin 
therapy. Theoretical Framework: Existing literature on transportation to healthcare access, the Social Determinants of 
Health, and the World Health Organization (WHO) dimensions of adherence will be used to develop a conceptual model that 
identifies factors of transportation that impacts health outcomes. Proposed Methods: Patients older than 21 years old and 
treated with warfarin will be recruited from an outpatient Antithrombosis Clinic (ATC) for an interview administered 
questionnaire as part of a larger study. Patients’ residential address and pharmacy locations will be geocoded using ESRI’s 
ArcGIS Online Geocode Service (ESRI, Redlands, CA) as longitude and latitude coordinates.3 Euclidean or straight-line distance 
will be used to calculate the travel distance between the patient and pharmacies. Anticoagulation control will be assessed by 
percent time in therapeutic range (%TTR) over 6 months using the Rosendaal’s method.4 The multivariate regression model 
will include pertinent socio-demographic factors, adherence, number of dispensing pharmacies, approximate travel time to 
pharmacy, travel barriers to pharmacy, availability of transportation, mode of transportation, and other relevant clinical 
factors that impact anticoagulation control.  
 
Key Words: Anticoagulation, Warfarin, Transportation, Distance, Dispending Pharmacy, Health Service Accessibility, 
Adherence  
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